CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07319026
NCT07319026N/ACompleted

Myeloid-derived Suppressor Cells: Characterization Of Their Role In Primary Myelofibrosis Pathogenesis For The Identification Of A New Therapeutic Target

Fondazione IRCCS Policlinico San Matteo di Pavia·observational·Posted Jan 6, 2026·Updated Jan 6, 2026

In Brief

An observational study for Primary Myelofibrosis (PMF) and Healthy Subjects. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The goals of this observational study are to investigate the role of myeloid-derived suppressor cells (MDSCs) in fueling chronic inflammation that is a relevant pathogenetic mechanism in patients with primary myelofibrosis (PMF), to study modifications in MDSC phenotype and function after treatment with JAK-inhibitors (JAK-i) and to test their participation in the neoangiogenic process. The main questions it aims to answer are: * Do the frequency and function of MDSCs contribute to induce or sustain the inflammatory status that characterizes PMF? * Does the number of circulating MDSCs in PMF patients correlate with clinical/biological parameters? * Are MDSCs involved in the neoangiogenic processes that characterizes PMF?

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedJan 6, 2026
Enrollment StartNov 14, 2023
Primary CompletionMar 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6 months ago